Antifungal resistance in pathogenic fungi

Clinical Infectious Diseases

Volumn 35, Issue 9, 2002, Pages 1073-1080

  Perea, Sofia ^a   Patterson, Thomas F ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ARTICLE; CORRELATION ANALYSIS; DRUG INDUCED DISEASE; DRUG SENSITIVITY; HUMAN; IMMUNE DEFICIENCY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SYSTEMIC MYCOSIS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FLUCYTOSINE; FORECASTING; HUMANS; IMMUNOCOMPROMISED HOST; MICROBIAL SENSITIVITY TESTS; PREVALENCE; TREATMENT OUTCOME;

EID: 0036828026     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344058     Document Type: Article

References (72)

1. Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev 1997; 10:477-504.
2. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infection. Clin Microbiol Rev 1996; 9:499-511.
3. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8:515-48.
4. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44:747-51.
5. Pfaller MA. Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22(Suppl 2):S89-94.
6. Pfaller MA, Messer SA, Gee S, et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 1999;37:870-2.
7. Pfaller MA, Lockhart SR, Pujol C, et al. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. J Clin Microbiol 1998; 36:1518-29.
8. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24:235-47.
9. Coleman DC, Rinaldi MG, Haynes KA, Rex JH, Summerbell RC, Anaissie EJ. Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol 1998; 36(Suppl 1):156-65.
10. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274-7.
11. Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-9.
12. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20:115-25.
13. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97:339-46.
14. Kirkpatrick WR, López-Ribot JL, Perea S, McAtee RK, Patterson TF. Natural history and evolution of the development of fluconazole resistance in Candida albicans populations colonizing and/or infecting the oral cavity of HIV-infected patients [abstract J1905]. In: Programs and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1999:577.
15. Marr KA, White TC, van Burik JAH, Bowden PA. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997; 25:908-10.
16. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - A prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52.
17. Nolte FS, Parkinson T, Falconer DJ, et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997; 41:196-9.
18. Mori T, Matsumura M, Kanamaru Y, et al. Myelofibrosis complicated by infection due to Candida albicans: Emergence of resistance to agents during therapy. Clin Infect Dis 1997; 25:1470-1.
19. Prasad R, de Wergifosse P, Goffeau A, Balzi E. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet 1995; 27: 320-9.
20. Sanglard D, Kuchler K, Ischer F, Pagani J-L, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39:2378-86.
21. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 143:405-16.
22. Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14β-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 1998; 42: 241-53.
23. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997; 41:1482-7.
24. White TC, Marr KA, Bowden PA. Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11:382-402.
25. Lopez-Ribot JL, McAtee RK, Lee LN, et al. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 1998; 42:2932-7.
26. Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, Patterson TF. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999; 43:1621-30.
27. Perea S, López-Ribot JL, McAtee RK, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans isolates displaying high-level fluconazole resistance from HIV-infected patients. Antimicrob Agents Chemother 2001; 45:2676-84.
28. Marr KA, Lyons CN, Rustad T, Bowden RA, White TC. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother 1998; 42:2584-9.
29. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 1999; 43:2753-65.
30. Moran GP, Sanglard D, Donnelly SM, Shanley DB, Sullivan DJ, Coleman DC. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 1998;42:1819-30.
31. Perea S, López-Ribot JL, Wickes BL, et al. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis Antimicrob Agents Chemother 2002; 46:1695-703.
32. Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998; 42:2645-9.
33. Nguyen M, Morris A, Dobson M, et al. Candida lusitaniae: An important emerging cause of candidemia. Infectious Diseases in Clinical Practice 1996; 5:273-8.
34. Dick JD, Rosengard BR, Merz WG, et al. Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii. Ann Intern Med 1985; 102:67-8.
35. Fan-Havard P, Capano D, Smith SM, et al. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother 1991; 35:2302-5.
36. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988; 84:826-32.
37. Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980; 18:158-63.
38. Kovacicova G, Hanzen J, Pisarcikova M, et al. Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors. J Infect Chemother 2001; 7:45-8.
39. Safe LM, Safe SH, Subden RE, Morris DC. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis. Can J Microbiol 1977; 23:398-401.
40. Yoon SA, Vasquez JA, Steffan PE, Sobel JD, Akins PA. High-frequency, in vitro switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother 1999; 43:836-45.
41. Barchiesi F, Arzeni D, Caselli F, Scalise G. Primary resistance to flucytosine among clinical isolates of Candida spp. J Antimicrob Chemother 2000; 45:401-12.
42. Whelan WL. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Crit Rev Microbiol 1987; 15:45-56.
43. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002; 46:1723-7.
44. Walmsley S, King S, McGeer A, Ye Y, Richardson S. Oropharyngeal candidiasis in patients with human immunodeficiency virus: Correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression. Clin Infect Dis 2001; 32:1554-61.
45. Nguyen MH, Clancy CJ, Yu VL, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998; 177:425-30.
46. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: Principal aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-58.
47. Keating GM, Jarvis B. Caspofungin. Drugs 2001; 61:1121-9.
48. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging antifungal agents. Clin Microbiol Rev 1999; 12:40-79.
49. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662-78.
50. 3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79:250-60.
51. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-805.
52. National Committee for Clinical and Laboratory Standards. Reference method for broth dilution antifungal susceptibility of conidium-forming filamentous fungi. Proposed standard. NCCLS document M38-P. Wayne, PA: National Committee for Clinical and Laboratory Standards, 1998.
53. Espinel-Ingroff A, Bartlett M, Chatuverdi V, et al. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp: NCCLS collaborative evaluation. Antimicrob Agents Chemother 2001; 45:1828-35.
54. Verweij PE, Mensink M, Rijs AJMM, Donnelly P, Meis JFGM, Denning DW. In vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 1998; 42:389-92.
55. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B acquired resistance to itraconazole. Scand J Infect Dis 1997; 29:509-12.
56. Dannaoui E, Persat F, Monier MF, Borel E, Piens MA, Picot S. In vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother 1999; 44:553-5.
57. Dannaoui E, Borel E, Persat F, Piens MA, Picot S. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol 2000; 49:601-6.
58. Dannaoui, Borel E, Monier MF, Piens MA, Picot S, Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2001; 47:333-40.
59. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40:401-14.
60. Dannaoui E, Borel E, Persat F, Monier MF, Piens MA. In vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus. J Med Microbiol 1999; 48:1087-93.
61. Brandt ME, Pfaller MA, Hajjeh RA, et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 2001; 45: 3065-9.
62. Casadevall A, Spitzer ED, Webb D, Rinaldi MG. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis. Antimicrob Agents Chemother 1993; 37:1383-6.
63. Paugam A, Dupovy-Camet P, Gaugneux JP, Tourte-Schafer C, Sicard D. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis 1994; 19:975-6.
64. Birley HDL, Johnson EM, McDonald P, Parry C, Carey PB, Warnock DW. Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int J STD AIDS 1995; 6:353-5.
65. Armengou A, Porcar C, Mascaro J, Garcia Bragado F. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996; 23: 1337-8.
66. Witt MD, Lewis RJ, Larsen RA, et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility, testing. Clin Infect Dis 1996; 22:322-8.
67. Aller AI, Martin-Mazuelos E, Lozano F, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal meningitis. Antimicrob Agents Chemother 2000; 44:1544-8.
68. Lamb DC, Corran A, Baldwin BC, Kwong-Chung J, Kelly SL. Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Lett 1995; 368:326-30.
69. Joseph-Horne T, Hollomon D, Loeffler RST, Kelly SL. Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother 1995; 39:1526-9.
70. 8→ isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett 1994; 122:39-42.
71. National Committee for Clinical and Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility of conidium-forming filamentous fungi: proposed standard. NCCLS document M38-P. Wayne, PA: NCCLS, 1998.
72. Perea S, Patterson TF. The role of antifungal susceptibility testing in the management of patients with invasive mycoses. Revista Iberoamericana Micologia 1999; 16:180-6.